

#### **Cautionary Note Regarding Forward-Looking Statements**

Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy





# We made the list!

TSXV: AVCR

We're proud to be recognized as one of Top 50 companies in 2023 on the TSX Venture Exchange

Learn more about the Venture 50 <u>here</u>, and watch our CEO, Hector Bremner speak on what this means for the company <u>here</u>.







The Problem

# Healthcare needs new tools.

Healthcare systems around the world are feeling
the strain of a reactive model that is costly and
ineffective. At Avricore Health, we believe in a more
accessible and proactive approach that empowers
patients and improves outcomes.



The Problem

# Chronic disease epidemic.

Chronic illness causes 71% of deaths worldwide and is responsible for the majority of the global burden of disease. Yet these conditions are preventable and can be managed proactively with medication and lifestyle modification.

Direct healthcare costs in \$68B Canada from chronic illness Canadians over 20 have one 50% or more chronic diseases Canadians currently has 1/3 diabetes or prediabetes




**Pharmacy Shift** 

# Pharmacy is transforming.

Pharmacies are investing in technology to facilitate the <u>future of their practice</u> as it shifts from pill dispensary to health consultancy.

As trusted health experts, pharmacists can then provide high value clinical services, such as early disease risk and prevention.







Market Potential

# Growth of POCT.

The point-of-care testing market is poised for significant growth over the next eight years to meet the increasing demand for fast, accurate health data in the community.







Digital Health Trend

# Empowered patients.

The digital health revolution is finally putting patients at the centre of their own care. With better access to actionable data, they can take an active role in achieving their health goals.



'HealthTab is focused on becoming the world's largest, most reliable POCT network in community pharmacies.'

- Hector Bremner

CEO, Avricore Health



HealthTab Solution

### Turnkey POCT for pharmacy.




HealthTab™ brings the best point-of-care analyzers onto a single, secure cloud-based network. It gives patients and pharmacists access to actionable data in real time, when it matters most.



### 23 biomarkers in minutes.

HealthTab™ provides fast, lab-accurate results for screening and monitoring chronic disease as well as testing for some common viral and bacterial infections. Data can be viewed immediately online.





Instruments

# Testing menu.

Through agreements with

Abbott Rapid Diagnostics,

HealthTab™ currently

supports the following

three POCT devices.





Tests:

A1c, Lipid Profile, C-Reactive Protein



**I-STAT** 

Tests:

Kidney Function, Electrolytes



**ID NOW** 

Tests:

RSV, Strep, Influenza A & B



Instruments

# **Expanding** our scope.

The Company also recently announced that in late 2023 the world's most accurate and popular blood glucose meter for people living with diabetes will be integrated into HealthTab.

This is the first time near-to-patient data will be reporting in patient's accounts, providing time-in-range data which will greatly enhance the pharmacists' ability to support meaningful consultations and advice.





Avricore Health Inc.



#### Revenue model.

**Pharmacies** 

100,000+

- Addressable market of community pharmacies in Canada, US & UK
- Currently in 416 Shoppers
   Drug Mart locations and entering growth phase

System Fee

\$250/mth

- Monthly cost to lease the system per location (based on a single instrument)
- Designed to be rapidly scaled through Abbott distribution agreement

Test Margin

30%

- HealthTab also generates revenue with each test (consumable reagents)
- Opportunities to drive volume include customized programs for health insurers and CROs



### Store earning estimates

Baseline

#### \$1000/mo

- Still training up and building in-store workflow
- Maybe experiencing staff limitations or expertise.

Focused

#### \$2000/mo

- Has at least one staff pharmacist assigned to services.
- Has become comfortable and is building client base

Superstars

#### \$4000/mo

- Makes a specific decision to focus on services, commits resources.
- Does not accept limitations, focused on yielding the maximum returns on services, with the high-margin value.



### **Network growth**

Current

Approx. 532

· Currently operating

2023

Approx. 1000

 Combination of Canadian and other market growth The following

### Approx. 2500

- Some pharmacy networks are in the several thousand locations in size.
- Regulatory and funding for screening in pharmacy is expected to be firm in most jurisdictions.



'We're proud to be a part of this amazing journey with HealthTab as we believe POCT in pharmacies is the future.'

Daniel Saint-PierreGM, Abbott Rapid Diagnostics



Competitive Advantage

#### The HealthTab difference.



1st to Market

Dedicated poct system for pharmacy



**Easily Integrated** 

API allows for seamless data integration



**Quality Control** 

World-class QC programs provided by CEQAL



**Pharmacy Focused** 

Expert knowledge of industry and operations



Harmonized Data

Single testing network for consistent results



**Patient Centered** 


Designed for convenience and quality of care



Canadian Superstore based Pharmacist Walk-In Clinics.

Avricore Health Inc.

TSXV: AVCR



**Shoppers Drug Mart** 

### Pilot Overview.

53

Pharmacies across Ontario participated

A1c

Initial focus was diabetes and heart disease markers

80% Patients learned some on new about their health Patients learned something



Shoppers Drug Mart Initial Pilot 2021-2022

### Pilot Patient Impacts.

- ✓ 6900 Patients, 15,000 tests completed
- ✓ On average, 31% received a new chronic medication
- ✓ 28% required a change in their current medication
- √ 235 patients were newly identified as diabetic

- ✓ Research has also shown that pharmacist-led care management resulted in lower total cost of care and fewer hospitalizations. These results demonstrate the important role that a pharmacist plays as a key member of the patient's health care team.
- √ 60 per cent of patients needed an intervention to better manage their chronic disease

"This pilot highlights the significant gap in access to treatment for those living with a chronic illness in Ontario. However, this pilot project also demonstrates that pharmacists can play a role in helping to close this critical healthcare gap by offering accessible, high-quality care."

- Justin Bates
CEO, Ontario Pharmacists Association.



Master Agreement

### Primary Care Innovation

With the expanded scope of practice for community pharmacists in Alberta, the Loblaws owned Real Canadian Superstore in Lethbridge opened a first-of-its-kind Pharmacist Walk-In Clinic. The site includes HealthTab to offer real-time POCT screening for diabetes and heart disease risk





### Roadmap 2023





**New Markets** 

### Going International





HealthTab™ has been selected by a collaborative involving the internationally renowned Barts Heart Centre and HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.

The feasibility study seeks deeper insights and ways to build off the successful delivery of over 930,000 blood pressure checks in just over a year through approximately 6000 pharmacies as part of NHS initiative to support risk identification and prevention of cardiovascular disease.



**POSSIBLE** SHARES **PROCEEDS ISSUED AND OUTSTANDING** 97,845,264 Appendix \$ CAD **PRICE EXPIRY DATE WARRANTS** Cap table. November 27, 2022 \$0.20 770.733 154,147 154.147 770.733 \$ CAD **EXPIRY DATE PRICE OPTIONS** \$0.10 December 8, 2022 65,000 650,000 \$0.10 March 27, 2023 20,000 200,000 \$0.10 April 11, 2023 15,000 150,000 \$0.08 January 24, 2024 10,500 140.000 April 1, 2024 \$0.06 140.000 8,400 October 15, 2024 \$0.05 73,500 1,470,000 \$0.08 November 18, 2025 500,000 40,000 \$0.08 December 8, 2025 56,800 710,000 \$0.19 January 28, 2026 28,500 150.000 March 22, 2026 \$0.25 450,000 1,800,000 August 10, 2027 \$0.15 408,750 2,725,000 1,176,450 8,635,000 **FULLY DILUTED** 107,250,997 1,330,597



Avricore Health Inc. 1120-789 West Pender St. Vancouver, BC, V6C 1H2 Contact info@avricore health.com

# Thank You